PP
SCPH

PDT Partners’s scPharmaceuticals SCPH Stock Holding History

PDT Partners’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,164
Closed -$69.1K – 815
2024
Q3 		$69.1K Sell
15,164
-2,187
-13% -$10.6K 0.01% 702
2024
Q2 		$75.5K Buy
+17,351
New +$76.2K 0.01% 647

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

PDT Partners's SCPH Position: Q4 2024 in Review

PDT Partners sold out of scPharmaceuticals (SCPH) in Q4 2024, closing a stake of 15,164 shares — an estimated $69.1K sold.

PDT Partners first reported a position in SCPH in Q2 2024 and held it in 2 quarters. The position peaked at $75.5K in Q2 2024. 85 funds tracked by Wall St. Rank hold SCPH as of Q4 2024.

  • PDT Partners reported no remaining scPharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • PDT Partners sold 15,164 scPharmaceuticals shares in Q4 2024, an estimated $69.1K.
  • PDT Partners first reported a position in scPharmaceuticals in Q2 2024 and held it in 2 quarters.
  • PDT Partners's scPharmaceuticals position peaked at $75.5K in Q2 2024.
  • 85 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2024.

Based on PDT Partners's 13F filing for Q4 2024, filed 14 Feb 2025.